Monitor the PTAB trial schedule and any related district court or ITC litigation for materiality. A final written decision finding claims unpatentable could affect Novartis's exclusivity for its anti-IgE food allergy therapy, but the current institution is only a procedural step.
NVS drugs
NVS drug pipeline →- ● Cosentyx 4/10 Approved (marketed); additional Phase 3 programs completed/terminated
- ● del-zota 4/10 Filed/PDUFA (BLA under Priority Review, Accelerated Approval pathway)
- ● Fabhalta 4/10 Approved (marketed); Phase 3 readout pending in aHUS
- ◆ ianalumab 4/10 Phase 3
- ● Scemblix 4/10 Approved (pivotal Phase 3 ASCEMBL completed; additional Phase 2/3 studies mostly completed or terminated)
- 16 more · All NVS drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $163.26entry
- T+1 · 6d ago −1.80%α −3.12% · $160.32
- T+4 · todayOpen
- T+5 · in 7h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outExecutive Summary
The PTAB granted institution of IPR2026-00260, allowing Amneal and Kashiv to challenge claims of Novartis's patent covering anti-IgE antibody therapy for multiple food allergies. As an interlocutory ruling, no claims have been cancelled, and the patent remains in force pending a final written decision.
PTAB Trial Details
Key Facts
- PTAB granted institution of IPR2026-00260 on November 10, 2026
- Patent U.S. 12030959 covers anti-IgE antibody therapy for multiple food allergies
- Patent owner is Genentech Inc. and Novartis Pharmaceuticals Corp. (Novartis AG subsidiary)
- Petitioners are Amneal Pharmaceuticals, Inc. and Kashiv Biosciences, LLC
- Institution is interlocutory; no claims have been cancelled
- A final written decision is expected within approximately one year
Financial Impact
Not stated in the decision; the patent's revenue contribution is not quantified
Risk Factors
- Institution granted means the patent faces a substantive challenge; a final written decision could cancel some or all claims
- The patent's revenue contribution to Novartis is not disclosed in the decision, making materiality uncertain
- Appeal to the Federal Circuit is possible after a final written decision
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 PTAB decision.
| Document | Accession Number |
|---|---|
| PTAB-TRIAL Data (Synthetic) | ptab-IPR2026-00260-ins-NVS |
Track record
16 reports on NVS
4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +6.86% at T+60 after the Jul 1, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 3/10 Entry $160.50 to $160.20 Now $160.20 −0.19% ▼ −0.19% +1.72% vs SPY
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Viewing Entry $163.26 to $160.32 Now $160.20 −1.87% ▼ −1.80% −3.12% vs SPY
- Oct 28, 202619d ago 144 Neutral 2/10 Entry $156.08 to $161.10 Now $160.20 +2.64% ▲ +3.22% +3.60% vs SPY
- Oct 27, 202620d ago 6-K Mixed 6/10 Entry $156.86 to $156.08 Now $160.20 +2.13% ▼ −0.50% −0.84% vs SPY
- Oct 15, 20264w ago Court Ruling Neutral 2/10 Entry $150.62 to $150.20 Now $160.20 +6.36% ▼ −0.28% −0.70% vs SPY
- Oct 13, 20265w ago Court Ruling Bearish 5/10 Entry $146.88 to $150.38 Now $160.20 −9.07% ▼ −2.38% −2.10% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $141.28 to $142.71 Now $160.20 +13.39% ▲ +1.01% +1.73% vs SPY
- Sep 4, 202610w ago 6-K Bearish 6/10 Entry $137.70 to $137.48 Now $160.20 −16.34% ▲ +0.16% −0.30% vs SPY
- Sep 1, 202610w ago 6-K Bullish 7/10 Entry $161.25 to $162.46 Now $160.20 −0.65% ▲ +0.75% +0.31% vs SPY
- Aug 4, 202615w ago Court Ruling Neutral 2/10 Entry $154.44 to $154.21 Now $160.20 +3.73% ▼ −0.15% +0.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time PTAB Decision Intelligence
Market-moving PTAB patent decisions analyzed within minutes. Trial institutions, denials, final written decisions, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers